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Objective: The present study was designed to determine the possible impact of hepatitis C virus (HCV) infection
on the expression of telomerase (TERT), retinoblastoma (RB1), E2F3, TP53, CDKN1A (p21) and fibroblast growth
factor receptor- 3 (FGFR3) genes in patients with bladder cancer (BC).
Materials and methods: 100 patients with bladder cancer (15 female and 85 male) were divided into 2 groups;
Group I: 50 HCV negative subjects (age range 36–79), and Group II: 50 HCV positive subjects (age range 42–80).
Expressions of the telomerase, retinoblastoma (Rb), E2F3, TP53 and FGFR3 genes were tested by
immunohistochemistry and real time PCR in tumour tissues and healthy bladder tissues. Also, telomerase activity
was assessed by telomeric repeats amplification protocol (TRAP).
Results: Bladder tumors associated with HCV infection were of high grade and invasive squamous cell carcinomas
(SCCs). Expressions of hTERT, Rb, E2F3, TP53 and FGFR3 as well as telomerase activity were significantly higher in
bladder tissues of HCV-infected patients compared with bladder tissues of non infected patients (p<0.05). On the
contrary, CDKN1A (p21) expression was significantly lower in bladder tissues of HCV-infected patients compared to
bladder tissues of non infected patients (p<0.05).
Conclusion: The expressions of hTERT, Rb, E2F3, TP53 and FGFR3 as well as the activity of telomerase were
significantly high in malignant bladder tissues associated with HCV infection. On the other hand, CDKN1A (p21)
expression was low in bladder tissues of HCV-infected subjects. Moreover, there was a positive correlation between
HCV infection and expression of telomerase, E2F3, TP53 and FGFR3. There was a negative correlation between HCV
infection and expression of Rb and p21.
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Bladder cancer (BC) in Egypt is the most prevalent
cancer in men (16%) and is the second most common
cancer in women, producing >7900 deaths annually,
which is strikingly higher than most other parts of the
world [1]. The pathogenesis of bladder cancer is a
complex process that involves the activation of proto-
oncogenes [2], inactivation or loss of tumor suppressor
genes [3] and mutations of cell cycle regulatory genes [4].* Correspondence: zizomenna28@yahoo.com
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distribution, and reproduction in any mediumTumour suppressor genes involved in development of
BC include retinoblastoma (Rb) and TP53 genes. Rb
gene mutations are seen in approximately 30% of BC
[5]. A recent study reported that Rb gene removal and
over expression of E2F3 may be required for bladder
carcinogenesis [6] as well as overexpression of TP53
[7]. Fibroblast growth factor receptor-3 (FGFR3) gene
is a proto-oncogene that promotes cell survival [8] and
mutations of the FGFR3 gene are associated with early
papillary lesions with low malignant potential [9,10].
These mutations have been found in 75% of non-
dysplastic genuine urothelial papillomas [10], indicating
that they are very early events in the papillary tumortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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regulator of cell cycle progression at G1 phase and al-
tered expression was demonstrated in more than half
of pT1 bladder tumors [7].
Telomerase is a specialized ribonucleoprotein complex
including an RNA component, human telomerase RNA
(hTR), and a catalytic protein, telomerase reverse transcript-
ase (hTERT), which stabilizes the telomeres of linear chro-
mosomes [11,12]. Expression of hTERT mRNA is very
closely associated with telomerase activity in human tumors
and can be detected by reverse transcription polymerase
chain reaction (RT-PCR) [13] and immunohistochemical
(IHC) methods [14]. Most human tumors display high
levels of telomerase activity [13,15]. Such expression in can-
cer cells might be a necessary step for tumor initial devel-
opment, progression [15] and plays an important role for
long-term maintenance [11,16]. Recently, Shaker et al. [17]
concluded that telomerase may be involved in the patho-
genesis of schistosomal BC and demonstrated an increase
in telomerase activity assessed by the telomeric repeats
amplification protocol (TRAP).
The role of hepatitis C virus (HCV) as an etiologic agent
of hepatocellular carcinoma (HCC) has been established
[18,19]. Also, there is a relationship between HCV infection
and other tumors such as oral squamous cell carcinoma
[20]. In a recent study, Gordon et al. was found that the
risk for renal cell carcinoma becomes nearly double in
patients with chronic hepatitis C infection [21]. In Egypt, in
the past, the incidence of schistosomiasis infection was
high, but nowadays, HCV infection predominates with ap-
proximately 10% to 20% of the population being infected
[22]. The frequency of histological cell type of bladder car-
cinoma was significantly changed over the past two decades
[23]. In a past report, squamous cell carcinoma (SCC)
predominated (59%) over transitional cell carcinoma (TCC)
(31%). Now, the relative frequency is 64% for TCC, 29% for
SSC, 5% for adenocarcinoma and 2% for undifferentiated
carcinoma. We hypothesized the change in histopatho-
logical profile of BC could be due to the change in the risk
factor. To test this hypothesis, we investigated in the
current study, the expression of telomerase (TERT), some
tumour suppressor gene (Rb, E2F3, TP53 and CDKN1A
(p21)) as well as some proto-oncogenes (FGFR3) that influ-
ence pathogenesis of BC in HCV infected patients and
compare their expressions with those in the non-HCV
infected patients. Expressions of these genes were corre-
lated with the clinic-pathological features of BC.
Subjects and methods
Subjects and study design
One hundred subject with bladder cancer (15 female
and 85 male) admitted to the Urology and Nephrology
Center at Mansoura University during the period from
Jan 2009 to Jan 2012 were enrolled in this study. Theywere divided into 2 main groups: Group I: 50 HCV nega-
tive subjects (age range 36–79). Group II: 50 HCV positive
subjects (age range 42–80). In each group, 2 samples were
taken from each enrolled subject, one from the malignant
tissue and the other from the healthy surrounding
urothelium. Tumor specimens and healthy urothelium
were taken by cystoscopy (transurethral resection biopsies,
TURB) and cystectomy. Patients were subjected to full
clinical examination (general and abdominal examination),
digital rectal examination (DRE), bimanual examination
under anesthesia, routine laboratory investigations (liver
function tests; albumin, bilirubin, and enzymes and kidney
functions test; serum creatinine and blood urea nitrogen
(BUN)), complete urine analysis, abdominal and pelvic
ultrasonography, plain x-ray of the urinary tract, intraven-
ous urography (IVU), and cystoscopy.
The study protocol was approved by the Ethical Com-
mittee of TBRI according to the Institutional Committee
for the Protection of Human Subjects and adopted by the
18th World Medical Assembly, Helsinki, Finland. Informed
consents from all patients who underwent cystoscopy and
biopsy from apparent growth and lesions were taken.
Patients with history of intravesical or systemic chemo-
therapy or immunotherapy -like mitomycin C or Bacillus
Calmette–Guérin (BCG) vaccine, radiotherapy, urinary
bilhariaziasis or smoking were excluded from this study.
Also, immunocompromized patients or those having
chronic cystitis were not included in this study.
Routine histopathology
Each specimen of bladder biopsy from malignant tissues
and normal urothelium was divided into two parts: a
small fresh part was frozen for PCR and the large portion
was fixed in 10% buffered formalin. The paraffin blocks
were retrieved and 3 μm thickness sections were prepared
for routine H&E. Other sections were prepared on
charged slides for immunohistochemistry. Examination of
slides from each specimen was done using Olympus CX51
light microscope. Pictures were obtained by a PC-driven
digital camera (Olympus E-620). The computer software
(Cell*, Olympus Soft Imaging Solution GmbH) enabled
analysis to be performed. In all cases a histopathological
diagnosis was made according to the World Health
Organization histological classification of urothelial tu-
mors [24].
Immunohistochemical examination of hTERT, Rb, p53,
FGFR3 and CDKN1A (p21)
Deparaffinized sections from all specimens were incubated
for 30 min with 0.3% hydrogen peroxide in methanol and
microwave heated in citrate buffer (pH 6.0) for 20 mi-
nutes. Subsequently, an indirect immunoperoxidase tech-
nique was applied, using monoclonal antibodies for
Telomerase (hTERT) (clone 2C4, concentrated with 1:500
Table 1 List of primers and probes used for the respective genes
Probe Reverse primer Forward primer Genes
5'FAM-CAGCACTTCTTTTGAGCACACGGTCG-3'TAMRA CAGTGGTTTAGGAGGGTTGCTT TTCCAGAAAATAAATCAGATGGTATGTAA Rb1
5'FAM- TTGCAAAGCATTGGAATCAGACAGCACT- 3'TAMRA CTCGGCCCTCTTTTCTCTG GCACTGGCTGATGAGTGTGT hTERT
AGCACCGCCGTCTGGTTGGC CGGCAGTGGCGGTGGTGGTG FGFR3
5'FAM-CTGTGACTTGCACGTACTCCCCTGCC- -3'TAMRA AAGACCTGCCCTGTGCAGC CGTCTGGGCTTCTTGCATTC TP53
5'FAM-CGGCAGACCAGCATGACAGATTTCTACCA-3'TAMRA GAGGAAGCCTAATCCGCC CTGGAGACTCTCAGGGTCGAAA CDKN1A (P21)
5'FAM-CAAGCTTCCCGTTCTCAGCC- 3'TAMRA GAAGATGGTGATGGGATTTC GAAGGTGAAGGTCGTAGTC GAPDH
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blastoma (Rb) (clone 1F8, prediluted; Thermo scientific,
catalogue No #MS-107-R7), TP53 (monoclonal mouse
anti-human antibody DO-7; Dako, Carpinteria, CA; dilu-
tion 1:4000), CDKN1A p21 (monoclonal mouse anti-
human, SX118, Dako; dilution 1:2000, FGFR3 (monoclonal
mouse anti-human, clone B-9; Santa Cruz Biotechnology).Table 2 Clinicopathological features of bladder cancers in






Age 57.6±8.59 57.9±9.45 NS
Minimum = 36 Minimum = 42
Maximum = 79 Maximum = 80
Sex
- Male 43 (86%) 42 (84%) NS
- Female 7 (14%) 8 (16%)
Histopathological type
- TCC 32 (64%) 19 (38%) p= 0.009
- SCC 18 (36%) 31 (62%)
Tumour grade
- Grade I 10 (20%) 26 (52%) p= 0.000
- Grade II 19 (38%) 19 (38%)
- Grade III 21 (42%) 5 (10%)
Lymph Nodes (LNs)
- Negative LNs 38 (76%) 40 (80%) NS
- Positive LNs 12 (24 %) 10 (20%)
Tumour staging
- Stage (Ta) 1 (2%) 5 (10%) p= 0.002
- Stage (T1) 12 (24%) 17 (34%)
- Stage (T2) 13 (26%) 15 (30%)
- Stage (T3) 12 (24%) 8 (16%)
- Stage (T4) 12 (24%) 5 (10%)
Metastases
- Negative 43 (86%) 42 (84%) NS
- Positive 7 (14%) 8 (16%)
P= chi square test with significance of p ≤ 0.05.Immunostaining was performed using Immuno-Pure
Ultra-Sensitive ABC Peroxidase (Thermo Scientific Cat.
No #32052) with (DAB) as chromogen. Proper positive and
negative controls were performed. Breast carcinoma was
used as positive control for Rb and TP53, pancreatic carci-
noma for telomerase and colorectal carcinoma for
CDKN1A (p21). As a negative control, sections were
stained without the addition of a primary antibody.Interpretation of immunohistochemical staining
As for the immunohistochemistry assessment, slides were
scanned by X40 magnification. Ten cellular areas were se-
lected (i.e. the so-called hot spots) and evaluated at X400
magnification. Telomerase immunostaining was considered
positive if at least 5% of the suspected cell population
showed positive intranuclear dot-like telomerase staining.
Quantitative assessment was done according to the method
of Yan et al. [25]. Labeled cells were expressed as a percen-
tage of tumor cells with positively stained nuclei divided by
the total number of tumor cell nuclei counted. As for Rb
expression, tumors were placed in one of two categories,
altered or normal. Tumors with normal expression
showed nuclear heterogeneous staining (less than 50%).
Tumors with no Rb expression and those with a strong
homogeneous staining pattern (more than 50%) were ca-
tegorized as having altered Rb status [26]. TP53 was consi-
dered positive when samples demonstrated at least 10%
nuclear immunoreactivity [27]. CDKN1A (p21) was consi-
dered altered when samples demonstrated no detectable or
only very low levels of CDKN1A (p21) nuclear staining
[26]. Expression of FGFR3 was evident as membranous and
cytoplasmic immunoreactivity, scored in a semi-quantitaive
scoring system: 0 = all tumor cells negative, 1 = weak posi-
tivity in more than 10% of tumor cells, 2 = moderate posi-
tivity and 3 = strong positivity/overexpression [27].
Real time PCR for studied genes
RNA extraction and cDNA synthesis
According to the manufacturer’s instructions, total
RNA from frozen tumor and from the corresponding
non-cancerous tissue specimens were isolated by dis-
ruption of 50–100 mg tissues in 1 ml of TRIzol











• hTERT by RT-PCR 0.13 ± 0.05 2.37 ± 0.44a 6.16 ± 0.57 ab 11.88 ±1.34 abc
• hTERT by IH (+ve cases) 3 (6%) 12 (24%) 24 (48%) 38 (76%)
Mean labeled cells 11.53 ± 2.82 14.90 ± 1.46 31.65 ± 9.02 44.36 ± 9.84
TRAP (ng/ml) 0.54 ± 0.24 2.98 ± 0.59 a 8.03 ± 1.26 ab 15.88 ± 1.94 abc
(positive cases) 2 (4%) 10 (20%) 32 (64%) 41 (82)
Tumour suppressor genes:
• Rb by RT-PCR 11.27 ± 1.42 6.92 ± 0.81 a 2.75 ± 0.65 ab 0.32 ± 0.30 abc
• Rb by IH (positive cases) 3 (6%) 12 (24%) 26 (52%) 40 (80%)
• E2F3 by RT-PCR 0.41 ±0.09 1.74 ± 0.47
a 3.60 ±1.22 ab 9.75 ± 4.32 abc
• TP53 by RT-PCR 0.25 ± 0.34 1.68 ± 0.29
a 3.92 ± 0.46 ab 12.39 ± 1.82 abc
• p53 by IH (positive cases) 0 (0%) 3 (6%) 21 (42%) 42 (84)
• P21 by RT-PCR 9.80 ± 0.45 5.83 ± 0.86
a 3.19 ± 0.45 ab 0.25 ±0.34 abc
• P21 by IH (positive cases) 49 (98%) 31 (62%) 13 (26%) 3 (6%)
Protooncogenes:
• FGFR3 by RT-PCR 0.08 ± 0.12 0.86 ± 0.76 3.06 ± 2.45 ab 2.87 ± 3.88 ab
• FGFR3 by IH (positive cases) 0 (0%) 2 (4%) 38 (76%) 48 (96%)
All data are expressed as Mean ± SD. One way ANOVA test with posthoc Scheffe’s test. a significant vs normal urothelium without HCV,
b significant vs normal urothelium with HCV, C significant vs malignant urothelium without HCV (p< 0.05).
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RNA was quantified spectrophotometrically and its
quality was determined by agarose gel electrophoresis
and ethidium bromide staining. Only samples that were
not degraded and showed clear 18 S and 28 S bands
under ultraviolet light were used for real-time PCR (RT-
PCR). Reverse transcription was performed using 1 μg
total RNA and the high capacity cDNA archive kit.Primers and probes
The primers and probes were purchased from Applied
Biosystems. All the primers and probes of the studied
genes are listed in Table 1.Real time PCR reaction
The reaction was performed using a total volume of
50 μl containing 25 μl 1× TaqMan® Universal PCR
Master Mix, 2.5 μl 20X TaqMan® Gene Expression
Assay Mix (which BRAND?) and 22.5 μl of cDNA di-
luted in RNase-free water. The cycling parameters were
as follows: initial denaturation at 95°C for 10 minutes,
followed by 40 cycles consisting of denaturation at 95°C
for 15 seconds, annealing at 60°C for 1 minute, exten-
sion at 72°C for 1 minute. Data analysis was carried out
using ABI prism 7000 by equation 2-ΔΔ ct [28].Assessment of telomerase activity using telomerase
repeat amplification protocol (TRAP)
Five sections from each paraffin embedded tissue speci-
mens were deparafinized by xylene, homogenized with
homogenizer in 200 μl of cold lysis buffer. After 30 mi-
nute of incubation on ice, the lysates were centrifuged
at 10,000 ×g for 30 min at 4°C. All steps were performed
according to a previously described technique [17]. The
assay kit (Telo-TAGGG Telomerase PCR ELISA plus)
was supplied by Roche (Roche Diagnostics, Mannheim,
Germany). The absorbance at 450 nm was determined.
To confirm product specificity, a negative control was
performed for each sample by heat inactivation of tel-
omerase at 85°C for 10 min. The relative telomerase ac-
tivity (RTA) in each sample was determined in relation
to IS and the control (provided within the kit) readings
using the formula provided by the manufacturers.
Statistical analysis
All statistical analyses were done using Statistical Program
for Social Sciences (SPSS 16.0). Qualitative data were
presented as numbers and percents, while quantitative
data were expressed as means ± SD. Chi-square test of
independence was used for evaluating the significant asso-
ciation of histopathology type, tumour grade, tumour in-
vasiveness, staging, and immunohistochemical staining of
tumour markers with HCV infected and non-HCV
Figure 1 Specimens of Transitional cell carcinoma (TCC). A = TCC with negativity for telomerase (hTERT), B = TCC with intranuclear dot like
positivity of hTERT in more than 25% of tumour cells from non-HCV infected patients, and C = TCC with intranuclear dot like positivity in more
than 50% of tumour cells from HCV infected patients (immunoperoxidase DAB X400).
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relation between 2 variables. A significant correlation
between two variables was taken at the 95% confidence
interval. Comparison between means of different groups
was done using one way ANOVA with Scheffe’s posthoc
test.Results
The clinicopathological features of bladder cancer in
HCV-infected and non-HCV infected patients
Bladder tumors associated with HCV infection were of the
transitional cell carcinoma (TCC) rather than squamous
cell carcinoma (SCC), high grade rather than low grade
and invasive rather than non-invasive. On the other hand,
there was no association between HCV-associated tumors
and LN affection, metastases and tumour staging. Also,
there was no significant association between age and sex
and HCV-associated tumours. Table 2 shows that HCV-
associated tumors occur in early age (minimum age was36 years); while non-HCV-associated tumours occur in
late age (minimum age was 42 years).Immunohistochemical localization of hTERT, Rb, TP53,
CDKN1A (P21) and FGFR3
The immunoreactivity for hTERT in tissue sections was
6.0% (3/50) in normal urothelium of non-HCV infected
patients (with mean labeled cells 11.53 ± 2.82), and 24%
(12/50) of normal urothelium of HCV infected patients
(with mean labeled cells 14.90 ± 1.46). Also, altered immu-
noreactivity for hTERT was 48% (24/50) in malignant
urothelium of non-HCV infected patients (with mean la-
beled cells 31.65± 9.02) and 76% (38/50) in malignant
urothelium of HCV infected patients (with mean labeled
cells 44.36 ± 9.84) (p < 0.001) (Table 3). hTERT immuno-
staining appeared as intranuclear dot like positivity which
was mainly localized in the nucleolus (Figure 1).
The immunoreactivity for Rb showed that the altered
expression for Rb protein was 6% (3/50) in normal
Figure 2 Specimens of Bladder Cancer. A = normal Rb heterogenous nuclear staining in less than 50% of tumor cells invasive carcinoma from
non-HCV infected patients, B = altered Rb expression; homogenous strong staining for Rb in more than 50% of tumor cells from HCV infected
patients and C = BC with negativity for Rb from HCV- infected patients (immunoperoxidase DAB X400).
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(12/50) in normal urothelium of HCV infected patients.
Also, altered immunoreactivity for Rb1 was 52 % (26/50)
in malignant urothelium of non-HCV infected patients,
and was 80% (40/50) in malignant urothelium of HCV
infected patients (p< 0.001) (Table 3). Rb1 immunostain-
ing appeared as strong homogenous nuclear staining
in >50% of tumor cells (Figure 2).
The immunoreactivity for TP53, CDKN1A (p21) and
FGFR3 proteins was 0% (0/50) for TP53, 98% (49/50)
for CDKN1A (p21), and 0% (0/50) for FGFR3 in nor-
mal urothelium of non-HCV infected patients and was
6% (3/50) for TP53, 62% (31/50) for CDKN1A (p21)
and 4% (2/50) for FGFR3 in normal urothelium of HCV –
infected patients (Table 3). The immunoreactivity was
42% (21/50) for TP53, 26% (13/50) for CDKN1A (p21)
and 76% (38/50) for FGFR3 in malignant bladder tissues
of non-infected patients, while the immunoreactivity was
84% (42/50) for TP53, 6% (3/50) for CDKN1A (p21) and
96% (48/50) for FGFR3 in bladder tumors associated
of HCV-infected patients (p< 0.001). Immunostaining
appeared as intranuclear positivity for TP53 (Figure 3),diffuse nuclear positivity for CDKN1A (p21) (Figure 4)
and diffuse cytoplamic positivity for FGFR3 (Figure 5).
Detection of telomerase activity by TRAP
In normal urothelium, TRAP activity was detected in 4%
(2/50) of non-infected patients and 20% (10/50) of HCV-
infected patients. But, TRAP activity in samples of malig-
nant tissues was 64% (32/50) in non-infected patients, and
82% (41/50) in HCV-infected patients. Also, compared to
normal urothelium of non-HCV infected patients, the ac-
tivity of telomerase by TRAP was significantly high in nor-
mal urothelium of non-infected subjects (p< 0.001). In
addition, TARP activity was significantly higher in malig-
nant urothelium of HCV-infected subjects compared to
malignant urothelium of non-infected subjects (Table 3).
Detection of expression of hTERT, Rb, E2F3, TP53,
CDKN1A (p21), and FGFR3 by real time RT-PCR
Quantitative real time PCR showed that the expression of
these genes was higher in normal urothelium of HCV-
infected patients compared to normal urothelium of non-
infected patients (p< 0.001), except FGFR3 which showed
Figure 3 Specimens of bladder urothelium. A = non-neoplastic urothelium with nuclear immunoreactivity for p53 in more than 10% of
urothelial cells, B = BC with nuclear immunoreactivity in less than 10% of tumor cells (scored negative) from non-HCV infected patients and C = BC
with increased p53 expression in more than 10 of tumour cells in invasive carcinoma from HCV-infected patients (Immunoperoxidase DAB X 400).
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genes was significantly higher in malignant tissues of HCV
infected patients compared to non-infected patients as
well as compared to normal urothelium of HCV-infected
and non-infected patients (p< 0.001) (Table 3).
On the other hand, Rb1, and CDKN1A (p21) gene
expression was significantly higher in normal urothelium
of non HCV infected patients compared to malignant tis-
sues of non-HCV infected patients as well as compared to
normal urothelium of HCV- infected and non-infected
patients (p< 0.001) (Table 3).
Correlations between HCV infection and expression of
hTERT, Rb, E2F3, TP53, CDKN1A (P21), and FGFR3
There was a positive correlation between HCV infection
and expression of hTERT, E2F3, TP53 and FGFR3 while
Rb and CDKN1A (p21) showed negative correlation with
HCV (p< 0.001) (Table 4).Survival analysis
The overall (OS) and disease free survival (DFS) curves
showed a statistically significant decrease in overall sur-
vival and disease free survival in patients with HCVaccompanied with bladder cancer (p = 0.047, p= 0.029
by Log-Rank test) (Figure 6).
Discussion
In the context of the many associations between a virus
and a given malignancy, the distinction between associ-
ated versus causative agent frequently arises and may be
difficult to make [29]. The major pathogenetic role
of HCV infection in hepatocellular carcinoma is well
documented [18,19]. The mechanism of its oncogenesis
remains unclear; however, alterations in cell cycle, proto-
oncogenes, tumour suppressor genes, apoptotic proteins,
telomeres are the key events in determining the biological
behavior of bladder cancer [2,17,30]. In the present study
we examined the expression of the telomerase and tumour
suppressor genes (Rb, E2F3, TP53, and CDKN1A; p21),
and proto-oncogenes (FGFR3) genes in HCV- and non-
HCV infected patient with bladder cancer.
In the present study we found that, the BC cases associ-
ated with HCV infection were of TCC type, higher grade,
and more invasive while, non-HCV-associated cancers
were of SCC type, lower grade, and less invasive tumors.
Moreover, the present study showed positive correlation
between TCC and HCV infection, suggesting that the
Figure 4 Specimens of bladder urothelium. A = non-neoplastic urothelium with no nuclear expression for p21 from HCV-infected patients,
B = Transitional cell carcinoma (TCC) with nuclear immunoreactivity for p21 in more than 10% of tumor cells from non-HCV infected patients and
C = lost p21 expression in most tumor cells from HCV infected patients (Immunoperoxidase DAB X 400).
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TCC cell type. On the other hand, Abdulamir et al., [31]
reported that schistosomal bladder tumors (SBT) were as-
sociated significantly with SCC, high grade, and invasive
tumors while non-SBT were associated with TCC, a bit
lower grade, and less invasive tumors.
Yoshida and Toge [32] hypothesized that telomerase
might be activated in early stages of urological carcino-
genesis. Expression of hTERT by real time PCR in the
present study showed significant increase in normal
urothelium of HCV infected patients as well as in malig-
nant bladder tissues from HCV infected patients. Also,
detection of hTERT by immunohistochemistry in tissue
samples showed expression in 6% in normal urothelium
from non- HCV infected patients and 24% in that from
HCV infected patients. In malignant tissues, immuno-
staining was 48% in samples from non-HCV infected pa-
tients with mean labeled cells 31.65± 9.02 and 76% in
samples from HCV-infected patients with mean labeled
cells 44.36 ± 9.84. We found that hTERT is localized
predominantly in the nucleolus and this is in agreement
with the few previous reports describing hTERT protein
localization [25,33] as the nucleolus is the site of nucleo-
protein complex assembly [34]. These findings suggestthat HCV infection enhances the expression of telomer-
ase enzyme in normal and malignant tissues. Also, the
activity of telomerase was evaluated by TRAP assay
which is the most widely used method for monitoring
telomerase activity. In this study, TRAP was positive in
4% of samples of normal urothelium from HCV-infected
patients and 20% from HCV infected patients. In malig-
nant tissues, TRAP was positive in 64% of non HCV
infected patients and 82% of HCV infected patients. De-
tection of telomerase activity in normal urothelium of
patients with BC suggests that telomerase might be acti-
vated in the early stages of BC carcinogenesis. Our find-
ings are in agreement with Yoshida and Toge [32] who
reported the activity of telomerase by TRAP in more
than 70% of bladder cancer and Abd El Gawad et al.
[35]. and Abdel-Salam et al. [36] who reported positivity
of TRAP in 73.9% of cases with bilharzial cancer and
87% for non bilharzial BC. The absence of telomerase
activity in some tumors may be due to the presence of a
telomerase inhibitor [17]. Also, the presence of a positive
correlation between HCV infection and TRAP and
hTERT expression suggests that HCV infection might
have a role in development and progression of BC espe-
cially of the TCC type.
Figure 5 Specimens of BC. A = urothelial carcinoma with faint but detectable membranous and cytoplasmic positivity in tumor cells for FGFR3
from non-HCV infected patients, B = BC with moderate cytoplasmic positivity in most tumor cells for FGFR3 from HCV infected patients and C =
BC with strong cytoplasmic positivity in tumor cells for FGFR3 from HCV infected patients (Immunoperoxidase DAB X400).
Table 4 Correlations of HCV infection to expression of




1. hTERT expression vs. HCV infection 0.931 0.000
2. Rb expression vs. HCV infection −0.901 0.000
3. E2F2 expression vs. HCV infection 0.427 0.000
4. p53 expression vs. HCV infection 0.730 0.000
5. p21 expression vs. HCV infection −0.567 0.000
6. FGFR3 expression vs. HCV infection 0.871 0.000
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of oncogenesis. We tested in our study retinoblastoma
(Rb), and TP53 genes. It appears conceivable that TP53
may negatively regulate the expression of genes through
the induction of p21/CDKN1A and the consecutive
hypophosphorylation of pRb and its relatives [37]. Ret-
inoblastoma tumor suppressor (Rb) gene encodes a nu-
clear phosphoprotein (pRb) that functions as a cell cycle
regulator [5]. Unphosphorylated pRb negatively regulates
E2F, a protein transcription factor, by binding with it.
The transcription factors E2f1, E2f2 and E2f3 act as pro-
moters of the G/S phase introduction, E2f4, E2f5, and
E2f6 are generally regarded either as weak transcrip-
tional activators or as transcriptional repressors [6]. This
protein species, in turn, binds to E2F family transcrip-
tion factors and converts them from transcriptional acti-
vators to transcriptional repressors [37]. When pRb is
phosphorylated by the cyclin/CDK complex, the tran-
scription factor E2F-1 is released and switches on genes
(e.g. thymidine synthetase) whose products drive cells
into the DNA synthesis (S) phase of the cell cycle. Nor-
mal cells express the Rb protein, while mutations or
gene deletions, which often result in lack of protein ex-
pression, may be identified by the lack of Rb expression[6]. Previous studies found that Rb gene mutations are
seen in approximately 30% of BC [5] and reported that
co-operation between (pRb) removal and over expres-
sion of E2F3 may be required for bladder carcinogenesis
[6]. In the present study, immunohistochemical detec-
tion of Rb protein in tissue samples of Rb expression
showed significant increase in altered expression (either
negative or increased homogenous positivity in >50% of
cells) in bladder tumors associated with HCV infection.
In addition, we found that Rb expression by RT-PCR
was decreased in bladder tumors from HCV infected pa-
tients. As an inhibitor of cyclin-dependent kinases, p21
Figure 6 Kaplan-Meier analysis for cases of BC. Patients with HCV infections showed significantly lower overall survival rate (A), and disease
free survival (positive case) (B).
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http://www.infectagentscancer.com/content/8/1/24is known to prevent the phosphorylation of retinoblast-
oma (Rb) [38] family proteins and hence lead to the
accumulation of hypophosphorylated pRb [39].
Also, we recorded overexpression of E2F3 in malig-
nant BC when compared to normal urothelium, andthis overexpression is enhanced by HCV infection.
Moreover, Rb had a negative correlation with HCV in-
fection, and positive correlation with TCC, while, it has
no correlation with the grade and invasiveness of blad-
der cancer.
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http://www.infectagentscancer.com/content/8/1/24Functional inactivation of TP53 is the most common
event in human malignancies, occurring in at least half of
all tumors [40]. In the present study, immunohistochemi-
cal detection of TP53 in tissue samples from normal
urothelium of non HCV infected patients revealed nega-
tive staining, while positivity was 6% of samples from nor-
mal urothelium from HCV-infected patients. Malignant
tissues from non-HCV infected patients showed positivity
in 42% of samples and those from HCV infected patients
showed positivity in 84% of samples. In consistence with
immunohistochemical findings, assay of TP53 by RT-PCR
showed significant increase in its expression in normal
urothelium from HCV-infected patients and in malignant
tissues from HCV infected patients. Moreover, TP53 ex-
pression showed positive correlation with HCV infection.
TP21 (CIP1/WAF1) cyclin kinase inhibitor protein; binds
to and inhibits the activity of cyclin-CDK2 or -CDK1 com-
plexes, and thus functions as a regulator of cell cycle pro-
gression at G1 [41]. The expression of this gene is tightly
controlled by the tumor suppressor protein TP53, through
which this protein mediates the TP53-dependent cell cycle
G1 phase arrest in response to a variety of stress stimuli.
Although, CDKN1A (p21) is a transcriptional target of the
tumor suppressor gene TP53, unfortunately, the present
study, showed significant loss in CDKN1A expression in
bladder tumors from HCV- infected patients. In addition,
we found low CDKN1A expression by RT-PCR in bladder
tumors from HCV infected patients. Moreover, CDKN1A
had a negative correlation with HCV infection. However,
we could not explain the cause for this controversy in de-
creased expression of CDKN1A in HCV infected patients
in contrast to TP53. Decreased or loss of CDKN1A expres-
sion in BC of HCV infected patients could be a sign for
bad prognosis in case of BC. In a previous study of patients
with advanced bladder carcinoma undergoing radical sur-
gery showed that patients with tumors that maintained
CDKN1A (p21) expression had increased survival relative
to patients with loss of CDKN1A expression [42].
The last tested gene is FGFR3 (proto-oncogene) which
is associated with early papillary lesions with low malig-
nant potential [9,10]. The mutations of FGFR3 are found
more frequently in superficial than in invasive urothelial
cell carcinoma (UCC) [9], and it has been reported that
such mutations are more frequent in UCCs that do not
recur [10]. Real time PCR and immunohistochemical
examination of FGR3 in the present study showed high
expression of FGFR3 in malignant bladder tissues from
HCV infected patients. Moreover, there is a positive cor-
relation between FGFR3 and HCV infection. Finally, an
interesting and novel finding in the present study was a
negative correlation between HCV infection and overall
survival rates and disease free survival.
Although, the present study was the first study, up to the
best of our knowledge, demonstrating altered expression oftelomerase, Rb, E2F3, TP53, CDKN1A (p21) and FGFR3 in
BC patient with HCV infection, it has some limitations.
This study did not investigate mutations of these genes in
BC of HCV infected patients. Moreover, the effect of HCV
on chromosomal stability, and DNA repair genes, hence
the behavior of bladder cancer, was not studied. Also, de-
creased overall survival and disease free survival rates of BC
with HCV may be due to other factors such as liver affec-
tion, other metabolites, medications, and immune system
alterations, and this point needs further exploration to
study the impact of these factors on survival of HCV
infected patients. This would be a future proposal for fur-
ther study and correlations.
Conclusion
HCV infection is associated with TCC of higher grade and
more invasiveness. The expression of hTERT, Rb, E2F3,
TP53 and FGR3 as well as the activity of telomerase were
significantly high in malignant bladder tissues associated
with HCV infection. On the other hand, CDKN1A (p21)
expression was significantly low in BC associated with
HCV infection. Moreover, there were positive correlations
between HCV infection and expressions of telomerase,
E2F3, TP53 and FGFR3 expression and negative correla-
tions between HCV infection and expression of Rb and
CDKN1A (p21) genes. Further studies are recommended
to investigate the possible role of HCV infection in patho-
genesis of bladder cancer. Furthermore, whenever the risk
factors are demonstrated using these tools, it might dictate
an additional new adjuvant therapy with surgery to im-
prove the survival of patients at high risk. Furthermore,
easily detection and treatment of active HCV infections
is warranted.
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